Amylyx Pharmaceuticals, Inc.
As of Oct 22, 2026, Amylyx Pharmaceuticals is in Stage 2, the uptrend phase, now in week 15 (since Jul 9, 2026). It closed at $28.57, 28.0% below its 52-week high and above its 200-day average, which is rising.
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Setup-score rank among Stage 2 peers: #1 of 26 in Drug Manufacturers - Specialty & Generic · #1 of 272 in Health Care
Is AMLX early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
AMLX among Drug Manufacturers - Specialty & Generic8th of 84 by relative strength
All 84 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | CPIX | Stage 2 · wk 23 | 98 | +6.8% |
| 2 | ETON | Stage 2 · wk 30 | 97 | −10.1% |
| 3 | ANIK | Stage 2 · wk 15 | 96 | +3.5% |
| 4 | IRWD | Stage 3 · wk 3 | 96 | −16.4% |
| 5 | TEVA | Stage 2 · wk 9 | 95 | +3.1% |
| 6 | AMRX | Stage 2 · wk 19 | 95 | +5.9% |
| 7 | KNSA | Stage 2 · wk 73 | 95 | +6.2% |
| 8 | AMLX | Stage 2 · wk 15 | 93 | −6.6% |
Amylyx Pharmaceuticals: quick answers
What stage is Amylyx Pharmaceuticals in?
As of Oct 22, 2026, Amylyx Pharmaceuticals (AMLX) is in Stage 2, the uptrend phase. It entered Stage 2 on Jul 9, 2026 and is in week 15. What the four stages mean
Is Amylyx Pharmaceuticals in an uptrend?
Yes. Amylyx Pharmaceuticals is in a Stage 2 uptrend. It trades 45.7% above its 200-day average, which is rising.
How far is Amylyx Pharmaceuticals from its 52-week high?
Amylyx Pharmaceuticals closed at $28.57 on Oct 22, 2026, 28.0% below its 52-week high of $39.66. Its 52-week low is $11.38.
How has Amylyx Pharmaceuticals performed over the past year?
As of Oct 22, 2026, Amylyx Pharmaceuticals is up 86.9% over the past year and up 150.2% so far in 2026.
Which sector and industry is Amylyx Pharmaceuticals in?
Amylyx Pharmaceuticals is in the Drug Manufacturers - Specialty & Generic industry, part of the Health Care sector.
About this companyHealth Care· Drug Manufacturers - Specialty & Generic
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.